SG11202003407VA - PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF - Google Patents

PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF

Info

Publication number
SG11202003407VA
SG11202003407VA SG11202003407VA SG11202003407VA SG11202003407VA SG 11202003407V A SG11202003407V A SG 11202003407VA SG 11202003407V A SG11202003407V A SG 11202003407VA SG 11202003407V A SG11202003407V A SG 11202003407VA SG 11202003407V A SG11202003407V A SG 11202003407VA
Authority
SG
Singapore
Prior art keywords
tbk
pyrimidine
inhibitor compounds
ikke
ikke inhibitor
Prior art date
Application number
SG11202003407VA
Inventor
Srinivasa R Karra
Yufang Xiao
Brian A Sherer
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11202003407VA publication Critical patent/SG11202003407VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202003407VA 2017-10-17 2018-10-17 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF SG11202003407VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762573251P 2017-10-17 2017-10-17
PCT/US2018/056190 WO2019079373A1 (en) 2017-10-17 2018-10-17 PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
SG11202003407VA true SG11202003407VA (en) 2020-05-28

Family

ID=64110185

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003407VA SG11202003407VA (en) 2017-10-17 2018-10-17 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF

Country Status (14)

Country Link
US (1) US20230019491A1 (en)
EP (1) EP3697772A1 (en)
JP (1) JP7266592B2 (en)
KR (1) KR20200072519A (en)
CN (1) CN111247135A (en)
AU (1) AU2018352699A1 (en)
BR (1) BR112020007466A2 (en)
CA (1) CA3078579A1 (en)
IL (1) IL273891A (en)
MX (1) MX2020003507A (en)
RU (1) RU2020115596A (en)
SG (1) SG11202003407VA (en)
TW (1) TWI802604B (en)
WO (1) WO2019079373A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018352701A1 (en) * 2017-10-17 2020-06-04 Merck Patent Gmbh Pyrimidine ΤΒΚ/ΙΚΚE inhibitor compounds and uses thereof
CN112552280A (en) * 2019-09-25 2021-03-26 常州强力先端电子材料有限公司 High-acid-yield sulfimide photo-acid generator
US20230015914A1 (en) * 2019-11-07 2023-01-19 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
CN117447407B (en) * 2023-12-19 2024-06-11 潍坊医学院 Preparation method of JAK2 inhibitor Pacritinib and intermediate thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2911139A1 (en) * 2007-01-05 2008-07-11 Sanofi Aventis Sa New 2,4-diaminopyrimidine derivatives useful for treating inflammatory diseases, diabetes or cancer
CA2698511C (en) 2007-09-04 2016-10-11 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
NZ599826A (en) * 2009-10-12 2014-08-29 Myrexis Inc Amino-pyrimidine compounds as inhibitors of ikk epsilon and/or tbk1
GB201012105D0 (en) * 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
CA2832919A1 (en) 2011-04-12 2012-10-18 Ryan C. Holcomb Compounds, compositions, and therapeutic uses thereof
DE102011112978A1 (en) 2011-09-09 2013-03-14 Merck Patent Gmbh benzonitrile derivatives
KR20180021702A (en) 2015-06-29 2018-03-05 메르크 파텐트 게엠베하 TBK / IKK? Inhibitor compounds and uses thereof

Also Published As

Publication number Publication date
RU2020115596A (en) 2021-11-18
CA3078579A1 (en) 2019-04-25
MX2020003507A (en) 2020-07-22
WO2019079373A1 (en) 2019-04-25
US20230019491A1 (en) 2023-01-19
IL273891A (en) 2020-05-31
EP3697772A1 (en) 2020-08-26
JP2020537671A (en) 2020-12-24
AU2018352699A1 (en) 2020-05-28
TWI802604B (en) 2023-05-21
BR112020007466A2 (en) 2020-09-24
CN111247135A (en) 2020-06-05
KR20200072519A (en) 2020-06-22
JP7266592B2 (en) 2023-04-28
RU2020115596A3 (en) 2021-11-18
TW201922735A (en) 2019-06-16

Similar Documents

Publication Publication Date Title
ZA201707641B (en) Tbk/ikke inhibitor compounds and uses thereof
IL273236A (en) Pyrazolopyrimidinone compounds and uses thereof
IL270330B (en) Beta-lactamase inhibitors and uses thereof
GB201605126D0 (en) Inhibitors and their uses
GB201714745D0 (en) New compounds and uses
EP3131877A4 (en) Guanidine compounds and use thereof
SG10201913927VA (en) Kinase inhibitors and uses thereof
EP3572400C0 (en) Ezh2 inhibitor and use thereof
HUE059778T2 (en) Urat1 inhibitor and use thereof
SI3621694T1 (en) Lrrc33 inhibitors and use thereof
IL263949A (en) Complement inhibitors and uses thereof
GB201714740D0 (en) New compounds and uses
GB201714734D0 (en) New compounds and uses
ZA201901773B (en) Pde4 inhibitor
SG11202004877UA (en) Sulfonamide compounds and use thereof
IL273891A (en) Pyrimidine tbk/ikke inhibitor compounds and pharmaceutical compositions containing them
IL262400A (en) Erbb inhibitors and uses thereof
IL247921A0 (en) Glutaminase inhibitor compounds, compositions comprising same and uses thereof
GB201714736D0 (en) New compounds and uses
GB201712110D0 (en) New compounds and uses
HK1255029A1 (en) Gelatinase inhibitors and use thereof
ZA202002825B (en) Pyrimidine τβκ/ικκε inhibitor compounds and uses thereof
IL265617B (en) 1-phenylpropanone compounds and use thereof
GB201720092D0 (en) New Compounds and uses
EP3442533A4 (en) Tg2 inhibitor compounds and uses thereof